Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 11/20 | 0.40 |
| ▸ | CA9 | Q16790 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871852 | 0.70 | CHRM3 (0.39) | ALDH1A1TSHRCA12CA9LMNA | |
| SCHEMBL10647946 | 0.69 | CA12 (0.40) | KMT2ATSHRCA12CA9LMNA | |
| SCHEMBL31635833 | 0.69 | PARP1 (0.34) | KMT2AKDM4EMEN1ALDH1A1GLA | |
| SCHEMBL6327672 | 0.67 | TRPA1 (0.36) | KMT2AKDM4EMEN1ALDH1A1GLA | |
| SCHEMBL1093499 | 0.64 | LMNA (0.44) | KMT2AKDM4EALDH1A1TSHRCA12 | |
| SCHEMBL5600204 | 0.63 | CA12 (0.59) | CA12CA9ALOX15CA2 | |
| SCHEMBL29476751 | 0.63 | CA12 (0.59) | CA12CA9ALOX15CA2 | |
| SCHEMBL31090834 | 0.62 | CA12 (0.50) | KDM4EALDH1A1HPGDTSHRCA12 | |
| SCHEMBL7911204 | 0.62 | CA12 (0.50) | KDM4EALDH1A1HPGDTSHRCA12 | |
| SCHEMBL7385174 | 0.61 | ALDH1A1 (0.42) | ALDH1A1HPGDTSHRCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | KMT2A 1270/4885KDM4E 2855/4885MEN1 976/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | KMT2A 1297/4885KDM4E 2625/4885MEN1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.